Risk factors
Gossamer Bio (GOSS) risk factors
Item 1A of every Gossamer Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks11 new5 dropped22 reworded
PROSERA missed its primary endpoint, putting seralutinib’s FDA path, further trials, financing needs, and commercialization in doubt.
Filed Mar 17, 2026 - FY2024 10-K risk factors72 risks
Company is pre-revenue and clinical-stage, relying heavily on the success, financing, and clinical trials of its lead product candidate, seralutinib.
Filed Mar 13, 2025